An Open-label Randomized Multinational Phase 3 Trial of Nivolumab Versus Docetaxel in Previously Treated Subjects With Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 078: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 078)

Trial Profile

An Open-label Randomized Multinational Phase 3 Trial of Nivolumab Versus Docetaxel in Previously Treated Subjects With Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 078: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 078)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Nivolumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CheckMate 078
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Apr 2018 Results published in the Bristol-Myers Squibb Media Release
    • 14 Mar 2018 According to the Bristol-Myers Squibb media release, data from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
    • 30 Nov 2017 According to a Bristol-Myers Squibb media release, Prof. Yi-Long Wu, a tenured professor of the Guangdong Lung Cancer Institute and the Guangdong General Hospital, chair of the Chinese Thoracic Oncology Group (CTONG) is the principal investigator of CheckMate -078 trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top